We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.11%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$64M
Cap. Flow
-$23.9M
Cap. Flow %
-0.91%
Top 10 Hldgs %
39.72%
Holding
198
New
11
Increased
45
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$17.5M
2
SYK icon
Stryker
SYK
+$12.2M
3
AZN icon
AstraZeneca
AZN
+$12.1M
4
DHR icon
Danaher
DHR
+$11.9M
5
PFE icon
Pfizer
PFE
+$11.1M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$13.6M
2
SHPG
Shire pic
SHPG
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$12.3M
4
ABT icon
Abbott
ABT
+$10.4M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.69M

Sector Composition

Rank Sector Weight
1 Healthcare 92.61%
2 Real Estate 3%
3 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHC
51
Diversified Healthcare Trust
DHC
$2.17B
$11.7M 0.44%
646,554
– –
BLUE
52
DELISTED
bluebird bio
BLUE
$11.3M 0.43%
5,574
+455
+9% +$1.04M
ISRG icon
53
Intuitive Surgical
ISRG
$126B
$11.2M 0.43%
70,437
+27,783
+65% +$4.24M
DPLO
54
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$11.2M 0.43%
439,001
– –
KYNB
55
Kyntra Bio
KYNB
$27.5M
$11.2M 0.42%
7,128
+2,956
+71% +$3.85M
ACHC icon
56
Acadia Healthcare
ACHC
$2.62B
$11.1M 0.42%
272,400
– –
PVLA
57
Palvella Therapeutics
PVLA
$2.15B
$10.6M 0.4%
26,092
– –
CRSP icon
58
CRISPR Therapeutics
CRSP
$4.77B
$10.5M 0.4%
178,348
+37,157
+26% +$2.12M
ENDP
59
DELISTED
Endo International plc
ENDP
$10.2M 0.39%
1,078,414
+163,866
+18% +$1.1M
ADAP
60
DELISTED
Adaptimmune Therapeutics
ADAP
$10.2M 0.39%
855,468
– –
GWPH
61
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$9.98M 0.38%
71,497
-39,287
-35% -$5.58M
BAX icon
62
Baxter International
BAX
$13.8B
$9.9M 0.38%
134,124
+94,159
+236% +$6.64M
EW icon
63
Edwards Lifesciences
EW
$50B
$9.65M 0.37%
198,825
– –
MRUS
64
DELISTED
Merus
MRUS
$9.43M 0.36%
414,115
-65,035
-14% -$1.21M
BPMC
65
DELISTED
Blueprint Medicines
BPMC
$9.27M 0.35%
146,001
+71,780
+97% +$5.71M
NKTR icon
66
Nektar Therapeutics
NKTR
$2.41B
$9.22M 0.35%
12,585
+4,284
+52% +$4.94M
EXEL icon
67
Exelixis
EXEL
$14.1B
$9.21M 0.35%
428,022
+39,200
+10% +$811K
CLLS
68
Cellectis
CLLS
$287M
$8.99M 0.34%
317,950
+34,700
+12% +$1.03M
LTC
69
LTC Properties
LTC
$2.06B
$8.96M 0.34%
209,673
– –
MDCO
70
DELISTED
Medicines Co
MDCO
$8.76M 0.33%
238,741
-39,650
-14% -$1.29M
ONC
71
BeOne Medicines Ltd
ONC
$33.4B
$8.42M 0.32%
54,785
+5,289
+11% +$943K
XLRN
72
DELISTED
Acceleron Pharma
XLRN
$8.29M 0.31%
170,766
-102,332
-37% -$3.73M
ESRX
73
DELISTED
Express Scripts Holding Company
ESRX
$8.22M 0.31%
106,500
– –
LKFT
74
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$8M 0.3%
86,815
-8,820
-9% -$856K
COR icon
75
Cencora
COR
$60.7B
$7.91M 0.3%
92,707
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Tekla Capital Management held 198 positions worth $2.64B, up 2.5% from $2.57B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2018 filing shows 11 new, 45 increased, 37 reduced and 18 closed positions. Its largest new stake was Whitehawk Therapeutics: 51,000 shares worth $3.17M. The largest sale was Sarepta Therapeutics, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q2 2018 buy was Whitehawk Therapeutics: 51,000 shares worth $3.17M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2018, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2018 reduction was Sarepta Therapeutics, cutting an estimated $13.6M.
  • Tekla Capital Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $8.69M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.64B portfolio in Q2 2018.
  • Tekla Capital Management opened 11 new positions and closed 18 in Q2 2018.
  • Tekla Capital Management's portfolio value rose 2.5% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.